TW202200617A - 對於btnl8具有特異性之抗體及其用途 - Google Patents

對於btnl8具有特異性之抗體及其用途 Download PDF

Info

Publication number
TW202200617A
TW202200617A TW110107678A TW110107678A TW202200617A TW 202200617 A TW202200617 A TW 202200617A TW 110107678 A TW110107678 A TW 110107678A TW 110107678 A TW110107678 A TW 110107678A TW 202200617 A TW202200617 A TW 202200617A
Authority
TW
Taiwan
Prior art keywords
btnl8
antibody
cells
seq
mab
Prior art date
Application number
TW110107678A
Other languages
English (en)
Chinese (zh)
Inventor
卡拉 卡諾
喬松 李
丹尼爾 奧莉薇
Original Assignee
法商感應檢查療法公司
法商英瑟姆公司
法國國家科學研究中心
尚波立及愛琳卡默茲中心
艾克斯 馬賽大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商感應檢查療法公司, 法商英瑟姆公司, 法國國家科學研究中心, 尚波立及愛琳卡默茲中心, 艾克斯 馬賽大學 filed Critical 法商感應檢查療法公司
Publication of TW202200617A publication Critical patent/TW202200617A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
TW110107678A 2020-03-04 2021-03-04 對於btnl8具有特異性之抗體及其用途 TW202200617A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305231 2020-03-04
EP20305231.1 2020-03-04

Publications (1)

Publication Number Publication Date
TW202200617A true TW202200617A (zh) 2022-01-01

Family

ID=71096647

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107678A TW202200617A (zh) 2020-03-04 2021-03-04 對於btnl8具有特異性之抗體及其用途

Country Status (2)

Country Link
TW (1) TW202200617A (fr)
WO (1) WO2021175954A1 (fr)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2156725A1 (fr) 1993-02-22 1994-09-01 Warren S. Pear Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0770628B9 (fr) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU7071598A (en) 1997-04-10 1998-10-30 Erasmus University Rotterdam Diagnosis method and reagents
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
WO2008119353A1 (fr) 2007-03-29 2008-10-09 Genmab A/S Anticorps bispécifiques et procédés de production de ceux-ci
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
EP2556086B1 (fr) * 2010-04-09 2015-03-04 Amgen Inc. Protéines btnl9, acides nucléiques, et anticorps et leurs utilisations
SG184427A1 (en) 2010-04-20 2012-11-29 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2019053272A1 (fr) 2017-09-15 2019-03-21 King's College London Compositions et procédés pour améliorer les lymphocytes t gamma delta dans l'intestin
JP7226833B2 (ja) 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体

Also Published As

Publication number Publication date
WO2021175954A1 (fr) 2021-09-10

Similar Documents

Publication Publication Date Title
JP7287963B2 (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
JP7269215B2 (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
JP7150880B2 (ja) 抗－ｂ７－ｈ３抗体およびその用途
CN111788225A (zh) 抗cd38抗体及与抗cd3和抗cd28抗体的组合
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
JP7226833B2 (ja) Ｂｔｎ２に特異性を有する抗体及びその使用
US10730946B2 (en) Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor
TWI764291B (zh) 抗tigit抗體及使用方法
US20230174670A1 (en) Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
AU2022285741A1 (en) Anti-ccr8 antibodies and uses thereof
CN117751143A (zh) 抗pvrig/抗tigit双特异性抗体和应用
TW202200617A (zh) 對於btnl8具有特異性之抗體及其用途
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
CN114957468A (zh) 一种抗Siglec15抗体及其用途
US20220162305A1 (en) Antibodies having specificity for btn2 and uses thereof
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
WO2024012513A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée
US20230374148A1 (en) Binding molecules that multimerise cd45
CN116438198A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体